ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1913

Investigation of the Cellular Mechanism for Estradiol-Induced Dermal Fibrosis

DeAnna Baker Frost1, Alisa Savchenko2, Adeyemi Ogunleye3, Milton Armstrong2 and Carol Feghali-Bostwick4, 1The Medical University of South Carolina, Charleston, 2Medical University of South Carolina, Charleston, SC, 3University of North Carolina Chapel Hill, Chapel Hill, NC, 4The Medical University of South Carolina, Charleston, SC

Meeting: ACR Convergence 2020

Keywords: Collagen, Fibroblasts, Dermal, Fibrosing syndromes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Estradiol (E2), one of the three forms of estrogen, is pro-fibrotic in the skin because it positively influences ECM production in the dermis. In addition to the direct influence that E2 has on ECM production, E2 also induces pro-fibrotic mediators such as TGFβ1 in a wound healing model1 2. Yet, few experiments discuss E2-induced pro-fibrotic mediator production or the transcriptional regulation of these protein(s). Since TGFβ1 is central in the development of organ fibrosis, especially in systemic sclerosis (SSc), delineating the regulation of TGFβ isoforms is important in understanding disease pathogenesis and developing potential therapeutics. Therefore, we investigated which ECM components are directly stimulated by E2-induced TGFβ signaling and the important regulatory proteins for TGFβ transcription and translation.

Methods: We received skin samples from healthy donors of various ages who underwent skin-resection procedures in the Division of Plastic Surgery at the Medical University of South Carolina under an approved IRB protocol. The ex-vivo human skin model organ culture was used as previously described3. Human primary dermal fibroblasts were isolated from human dermal tissue using the outgrowth method4. For experimentation, we used 6-well tissue culture dishes with 4-3mm punches/well or fibroblasts plated at 1.5-2.0 x 105 cells/well in serum-free, phenol red-free DMEM. Steady-state mRNA levels were measured using quantitative PCR (qPCR) and signals normalized to B2M and GAPDH levels. Primary dermal fibroblasts were transfected with siRNA targeted to early growth response 1 (EGR1) or control prior to vehicle or E2 treatment.

Results: We report that the transcription of TGFβ1, TGFβ2 and collagen 22A1 (Col22A1), the TGFβ responsive gene, are induced in response to E2 stimulation in vitro and ex vivo. Mechanistically, Col22A1 induction is blocked by the TGFβ receptor inhibitor SB-431542 despite E2 stimulation. Additionally, blocking E2-induced MAPK activation and EGR1 transcription inhibit TGFβ1, TGFβ2 and Col22A1 transcription.

Conclusion: We conclude that E2-induced dermal fibrosis occurs in part through induction of TGFβ1, TGFβ2 and Col22A1 which is regulated though EGR1 and the MAPK pathway. Dermal fibrosis is a feature of pro-fibrotic diseases, such as SSc, emphasizing the necessity to understand the underlying mechanism of fibrosis. Here, we suggest a cell signaling mechanism for E2-induced fibrosis and TGFβ regulation. Based on the realization that E2-induced TGFβ1 and TGFβ2 directly increase Col22A1 and contribute to ECM accumulation, therapies that inhibit E2 signaling may reduce dermal fibrosis and present a novel therapeutic alternative in pro-fibrotic diseases.


Disclosure: D. Baker Frost, None; A. Savchenko, None; A. Ogunleye, None; M. Armstrong, None; C. Feghali-Bostwick, None.

To cite this abstract in AMA style:

Baker Frost D, Savchenko A, Ogunleye A, Armstrong M, Feghali-Bostwick C. Investigation of the Cellular Mechanism for Estradiol-Induced Dermal Fibrosis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/investigation-of-the-cellular-mechanism-for-estradiol-induced-dermal-fibrosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigation-of-the-cellular-mechanism-for-estradiol-induced-dermal-fibrosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology